Learn More About OCUDOSE®
Don’t miss out on any important information. Sign up today to receive free materials about TIMOPTIC® in OCUDOSE®, including the latest news and updates.
Enter your information in the fields below:
Protecting Your Privacy
In order to provide you with a better Web site experience and better features in the future, we ask you for your e-mail address. If you provide this data, you agree to allow Valeant to link your e-mail address to anonymous (non−personally-identifiable) information that you may have given us previously, or that may have been collected on other Valeant Web sites. We will not sell your e-mail address, and you will not receive e-mail from us that you have not agreed to receive.
INDICATIONS AND USAGE
Preservative-free TIMOPTIC® in OCUDOSE® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free TIMOPTIC® in OCUDOSE® may be used when a patient is sensitive to the preservative in Timoptic (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.
IMPORTANT SAFETY INFORMATION
Timoptic is contraindicated in patients with: bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; hypersensitivity to any component of this product.
This drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. Severe respiratory or cardiac reactions, including death, have been reported following systemic or ophthalmic administration of timolol maleate. Timoptic should be used with caution in patients with cerebrovascular insufficiency.
The most frequently reported adverse experiences have been burning and stinging upon instillation.
Please see full Prescribing Information by clicking on the link above.